Literature DB >> 20650430

Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.

Ronen Jaffe1, Alexander Dick, Bradley H Strauss.   

Abstract

Microvascular obstruction (MVO) commonly occurs following percutaneous coronary interventions (PCI), may lead to myocardial injury, and is an independent predictor of adverse outcome. Severe MVO may manifest angiographically as reduced flow in the patent upstream epicardial arteries, a situation that is termed "no-reflow." Microvascular obstruction can be broadly categorized according to the duration of myocardial ischemia preceding PCI. In "interventional MVO" (e.g., elective PCI), obstruction typically involves myocardium that was not exposed to acute ischemia before PCI. Conversely "reperfusion MVO" (e.g., primary PCI for acute myocardial infarction) occurs within a myocardial territory that was ischemic before the coronary intervention. Interventional and reperfusion MVO have distinct pathophysiological mechanisms and may require individualized therapeutic approaches. Interventional MVO is triggered predominantly by downstream embolization of atherosclerotic material from the epicardial vessel wall into the distal microvasculature. Reperfusion MVO results from both distal embolization and ischemia-reperfusion injury within the subtended ischemic tissue. Management of MVO and no-reflow may be targeted at different levels: the epicardial artery, microvasculature, and tissue. The aim of the present report is to advocate a systematic approach to prevention and treatment of MVO in different clinical settings. Randomized clinical trials have studied strategies for prevention of MVO and no-reflow; however, the efficacy of measures for reversing MVO once no-reflow has been demonstrated angiographically is unclear. New approaches for prevention and treatment of MVO will require a better understanding of intracellular cardioprotective pathways such as the blockade of the mitochondrial permeability transition pore. Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650430     DOI: 10.1016/j.jcin.2010.05.004

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  54 in total

1.  Olfactory ensheathing cells promote neurite sprouting of injured axons in vitro by direct cellular contact and secretion of soluble factors.

Authors:  R S Chung; A Woodhouse; S Fung; T C Dickson; A K West; J C Vickers; M I Chuah
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

2.  Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow.

Authors:  Koya Ozawa; William Packwood; Oleg Varlamov; Yue Qi; Aris Xie; Melinda D Wu; Zaverio Ruggeri; Jose A López; Jonathan R Lindner
Journal:  Circ Cardiovasc Imaging       Date:  2018-11       Impact factor: 7.792

3.  The value of plasma D-dimer level on admission in predicting no-reflow after primary percutaneous coronary intervention and long-term prognosis in patients with acute ST segment elevation myocardial infarction.

Authors:  Ayhan Erkol; Vecih Oduncu; Burak Turan; Alev Kılıçgedik; Dicle Sırma; Gökhan Gözübüyük; Can Yücel Karabay; Ahmet Guler; Cihan Dündar; Kürşat Tigen; Selçuk Pala; Cevat Kırma
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

Review 4.  Management of Percutaneous Coronary Intervention Complications.

Authors:  Gregory Means; Christopher End; Prashant Kaul
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

5.  The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Alaa Quisi; Gökhan Alıcı
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

6.  A simple and rapid method for identification of lesions at high risk for the no-reflow phenomenon immediately before elective coronary stent implantation.

Authors:  Akira Suda; Shigeto Namiuchi; Tomohiro Kawaguchi; Taro Nihei; Toru Takii; Kenya Saji; Tadashi Sugie; Atsushi Kato; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2016-03-02       Impact factor: 2.037

7.  Link between aortic valve sclerosis and myocardial no-reflow in ST-segment elevation myocardial infarction.

Authors:  L Korkmaz; H Erkan; M T Ağaç; E Pelit; H Bektas; Z Acar; I Gurbak; F Kara; Ş Çelik
Journal:  Herz       Date:  2014-01-19       Impact factor: 1.443

8.  Prostaglandin E1 protects coronary microvascular function via the glycogen synthase kinase 3β-mitochondrial permeability transition pore pathway in rat hearts subjected to sodium laurate-induced coronary microembolization.

Authors:  Houyong Zhu; Yu Ding; Xiaoqun Xu; Meiya Li; Yangliang Fang; Beibei Gao; Hengyi Mao; Guoxin Tong; Liang Zhou; Jinyu Huang
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

9.  MRI quantification of left ventricular function in microinfarct versus large infarct in swine model.

Authors:  Maythem Saeed; Steve W Hetts; Loi Do; Sammir M Sullivan; Mark W Wilson
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-13       Impact factor: 2.357

10.  Left circumflex coronary artery is protected against no-reflow phenomenon following percutaneous coronary intervention for coronary artery disease.

Authors:  Toshiyuki Nagai; Takuro Hirano; Mayumi Tsunoda; Haruhiko Hosaka; Yoshikazu Kishino; Takaharu Katayama; Keisuke Matsumura; Takashi Miyagawa; Shun Kohsaka; Toshihisa Anzai; Keiichi Fukuda; Masahiro Suzuki
Journal:  Heart Vessels       Date:  2012-09-12       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.